Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
LianBio Sponsored ADR (LIAN)
NASDAQ:LIAN
LianBio Sponsored ADR (LIAN) Stock Price & Analysis
60 Followers
LIAN Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$0.06 - $0.39
Previous Close$0.35
Volume23.23M
Average Volume (3M)925.76K
Market Cap
N/A
Enterprise ValueN/A
Total Cash (Recent Filing)$252.22M
Total Debt (Recent Filing)$2.84M
Price to Earnings (P/E)-0.4
Beta0.55
Next Earnings
Mar 26, 2024EPS Estimate
-$0.19Last Dividend Ex-Date
Mar 15, 2024Dividend YieldN/A
Share Statistics
EPS (TTM)-0.82
Shares Outstanding108,062,638
10 Day Avg. Volume2,577,171
30 Day Avg. Volume925,757
Standard Deviation0.40
R-Squared0.00103
Alpha0.02
Financial Highlights & Ratios
Price to Book (P/B)0.19
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-6.80
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda0.00
Forecast
1Y Price Target
$3.50Price Target Upside906.33% Upside
Rating ConsensusModerate Sell
Number of Analyst Covering2
LianBio Sponsored ADR News
PremiumCompany Announcements
LianBio ADR Initiates Wind-Down and Announces Special Dividend
PremiumPress Releases
LianBio Announces Completion of Strategic Review
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
LIAN FAQ
What was LianBio Sponsored ADR’s price range in the past 12 months?
LianBio Sponsored ADR lowest stock price was $0.06 and its highest was $0.39 in the past 12 months.
What is LianBio Sponsored ADR’s market cap?
Currently, no data Available
When is LianBio Sponsored ADR’s upcoming earnings report date?
LianBio Sponsored ADR’s upcoming earnings report date is Mar 26, 2024 which is 23 days ago.
How were LianBio Sponsored ADR’s earnings last quarter?
LianBio Sponsored ADR released its earnings results on Nov 13, 2023. The company reported -$0.22 earnings per share for the quarter, beating the consensus estimate of -$0.33 by $0.11.
Is LianBio Sponsored ADR overvalued?
According to Wall Street analysts LianBio Sponsored ADR’s price is currently Undervalued.
Does LianBio Sponsored ADR pay dividends?
LianBio Sponsored ADR pays a Notavailable dividend of $4.75 which represents an annual dividend yield of N/A. See more information on LianBio Sponsored ADR dividends here
What is LianBio Sponsored ADR’s EPS estimate?
LianBio Sponsored ADR’s EPS estimate is -$0.19.
How many shares outstanding does LianBio Sponsored ADR have?
LianBio Sponsored ADR has 108,062,640 shares outstanding.
What happened to LianBio Sponsored ADR’s price movement after its last earnings report?
LianBio Sponsored ADR reported an EPS of -$0.22 in its last earnings report, beating expectations of -$0.33. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of LianBio Sponsored ADR?
Among the largest hedge funds holding LianBio Sponsored ADR’s share is Perceptive Advisors LLC. It holds LianBio Sponsored ADR’s shares valued at 257M.
---
LianBio Sponsored ADR Stock Smart Score
Not Ranked
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Sell
Average Price Target:
$3.50 (906.33% Upside)
$3.50 (906.33% Upside)
Crowd Wisdom
Very Positive
Last 7 Days ▲ 2.8%
Last 30 Days ▲ 3.5%
Last 30 Days ▲ 3.5%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
333.75%
12-Months-Change
Fundamentals
Return on Equity
-36.90%
Trailing 12-Months
Asset Growth
-25.28%
Trailing 12-Months
Company Description
LianBio Sponsored ADR
LianBio is a science-driven biopharmaceutical company dedicated to developing and commercializing innovative medicines for patients with unmet medical needs, with an initial focus on in-licensing assets for Greater China and other Asian markets. It is advancing a diversified portfolio of clinically validated product candidates with the potential to drive new standards of care across cardiovascular, oncology, ophthalmology, inflammatory disease and respiratory indications.
---
LIAN Stock 12 Months Forecast
Average Price Target
$3.50
▲(906.33% Upside)
Technical Analysis
Best Analysts Covering LIAN
1 Year
1 Year Success Rate
1/3 ratings generated profit
1 Year Average Return
-10.53%
downgraded a sell rating 4 months ago
Copying Geoff Meacham's trades and holding each position for 1 Year would result in 33.33% of your transactions generating a profit, with an average return of -10.53% per trade.
---